AstraZeneca Signs US Agreement With Teva
Under the terms of the settlement agreement, AstraZeneca has granted Teva a license to enter the US market with its generic version of oral budesonide on 15 February 2012, subject to regulatory approval, or earlier in certain circumstances. Teva has conceded that both patents-in-suit in Teva’s US EC patent litigation are valid and enforceable.
Teva has also conceded that both Entocort patents-in-suit would be infringed by the manufacture or sale of Teva’s generic version of oral budesonide. The US District Court for the District of Delaware will enter a consent judgment and the corresponding patent litigation will be dismissed.
Other terms of the settlement are confidential.
Merck Sharp & Dohme (formerly Merck & Co.) through KBI and KBI-E, and under the terms of Merck's restructured partnership with AstraZeneca, announced in 1998, also entered into the settlement agreement.
Will Teva benefit in the new agreement?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.